Balloon-Expandable Stent Placement in Patients with Immediate Reocclusion after Initial Successful Thrombolysis of Acute Middle Cerebral Arterial Obstruction

Abstract

We present the results of our approach for treating 12 consecutive cases of acute middle cerebral artery (MCA) stroke by performing balloon-expandable stent (BES) placement after immediate reocclusion due to the underlying stenosis after intra-arterial thrombolysis (IAT).

We retrospectively reviewed the clinical outcomes of 12 patients with acute MCA stroke who underwent recanalization by BES placement in an underlying stenosis after IAT. The time to treatment, urokinase dose, duration of the procedure, recanalization rates and symptomatic hemorrhage were analyzed. Clinical outcome measures were assessed on admission and at discharge (the National Institutes of Health stroke scores [NIHSS]) as well as three months after treatment (modified Rankin scales [mRS]).

The median NIHSS score on admission was 8.6. Four patients received IV rtPA. The median time from symptom onset to IAT was 236 minutes and the median duration of IAT was 62 minutes. The median dose of urokinase was 140,000 units. Initial recanalization after stent deployment (thrombolysis in cerebral ischemia attack grade of II or III) was achieved in all patients. Two patients died in the hospital due to aspiration pneumonia during medical management. In two patients, in-stent reocclusion occurred within 48 hours after stent deployment. At discharge, the median NIHSS score in ten patients (including the patients with reobstruction) was 2.4. The three-month outcome was excellent (mRS, 0–1) in eight patients.

In this study, BES deployment was safe and effective in patients with an immediately reoccluded MCA after successful IAT.

Keywords

stroke stent atherosclerosis thrombolysis middle cerebral artery

Get full access to this article

View all access options for this article.

References

Wityk

Lehman

Klag

. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke. 1996; 27: 1974–1980.

Feldmann

Daneault

Kwan

. Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology. 1990; 40: 1541–1544.

Sacco

Kargman

. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: The Northern Manhattan Stroke Study. Stroke. 1995; 26: 14–20.

Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology. 2003; 22: 106–117.

Chimowitz

Kokkinos

Strong

. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995; 45: 1488–1493.

Kasner

Chimowitz

Lynn

. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006; 113; 555–563.

Qureshi

Siddiqui

Kim

. Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. Am J Neuroradiol. 2004; 25: 322–328.

Heo

Lee

Kim

. Immediate reocclusion following a successful thrombolysis in acute stroke: A pilot study. Neurology. 2003; 60: 1684–1687.

Connors

3rd Wojak

. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: Evolution of technique and short-term results. J Neurosurg. 1999; 91: 415–423.

10.

Bose

Hartmann

Henkes

. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: The Wingspan study. Stroke. 2007; 38: 1531–1537.

11.

Marks

Wojak

Al-Ali

. Angioplasty for symptomatic intracranial stenosis: Clinical outcome. Stroke. 2006; 37: 1016–1020.

12.

Zaidat

Klucznik

Alexander

. The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology. 2008; 70: 1518–1524.

13.

Levy

Ecker

Horowitz

. Stent-assisted intracranial recanalization for acute stroke: Early results. Neurosurgery. 2006; 58: 458–463.

14.

Sauvageau

Samuelson

Levy

. Middle cerebral artery stenting for acute ischemic stroke after unsuccessful Merci retrieval. Neurosurgery. 2007; 60: 701–706.

15.

Noser

Shaltoni

Hall

. Aggressive mechanical clot disruption; a safe adjunct to thrombolytic therapy in acute stroke? Stroke. 2005; 36: 292–296.

16.

Yoon

Park

Cho

. Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute ischemic stroke after failure of intravenous thrombolysis. Am J Neuroradiol. 2010; 31: 161–164.

17.

Gobin

Starkman

Duckwiler

. MERCI 1: A phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke. 2004; 35: 2848–2854.

18.

Castao

Dorado

Guerrero

. Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: A pilot study. Stroke. 2010; 41: 1836–1840.

19.

Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009; 40: 2761–2768.

20.

Kelly

Furlan

Fiorella

. Recanalization of an acute middle cerebral artery occlusion using a self-expanding, reconstrainable, intracranial microstent as a temporary endovascular bypass. Stroke. 2008; 39: 1770–1773.

21.

Nakano

Iseda

Yoneyama

. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: An alternative option to intra-arterial thrombolysis. Stroke. 2002; 33: 2872–2876.

22.

Marks

Marcellus

. Intracranial angioplasty without stenting for symptomatic atherosclerotic stenosis: Long-term follow-up. Am J Neuroradiol. 2005; 26: 525–530.

23.

Yoon

Seo

Cho

. Symptomatic middle cerebral artery stenosis treated with intracranial angioplasty: Experience in 32 patients. Radiology. 2005; 237: 620–626.

24.

Siddiq

Vazquez

Memon

. Comparison of primary angioplasty with stent placement for treating symptomatic intracranial atherosclerotic diseases. A multicenter study. Stroke. 2008; 39: 2505–2510.

25.

Suh

Kim

Chol

. Intracranial stenting of severe symptomatic intracranial stenosis: Results of 100 consecutive patients. Am J Neuroradiol. 2008; 29: 781–785.

26.

Steinhubl

Talley

Braden

. Point-of-case measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaenous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001; 103: 2572–2578.

27.

Walter

Schächinger

Elsner

. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997; 350: 1217–1219.

28.

Nahab

Lynn

Kasner

. Risk factors associated with major cerebrovascular complications after intracranial stenting. Neurology. 2009; 72: 2014–2019.

29.

Henkes

Miloslavski

Lowens

. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (Wing-Span). Neuroradiology. 2005; 47: 222–228.

30.

Yue

Yin

. Comparison of BMSs with SES for symptomatic intracranial disease of the middle cerebral artery stenosis. Cardiovasc Intervent Radiol. 2011; 34: 54–60.

31.

Leung

Lam

. Would self-expanding stent occlude middle cerebral artery perforators? Stroke. 2009; 40: 1910–1912.

32.

Levy

Chaturvedi

. Perforator stroke following intracranial stenting: A sacrifice for the greater good? Neurology. 2006; 66: 1803–1804.